Nilotinib Aenorasis

Nilotinib, the active ingredient in Nilotinib Aenorasis, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients. GNH USA supplies Nilotinib Aenorasis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib targets BCR‑ABL driven malignancies within the chronic myeloid leukemia and acute lymphoblastic leukemia disease families. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves hematologic and cytogenetic response. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: provides targeted inhibition of BCR‑ABL to achieve remission. - CML after imatinib resistance: offers an alternative tyrosine kinase inhibitor to regain disease control.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects: - QT interval prolongation: may cause cardiac arrhythmias. - Arterial occlusive events: risk of heart attack or stroke. - Pancreatitis: inflammation of the pancreas. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hyperglycemia: significant rise in blood glucose levels.

Patients should be monitored for cardiovascular and metabolic effects before and during therapy. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT prolongation risk. - Liver function: assess baseline enzymes and monitor during treatment. - Blood glucose: check fasting glucose regularly. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that may increase nilotinib exposure. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and light.

Nilotinib has several clinically relevant drug interactions that require attention. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma nilotinib levels. - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: can reduce nilotinib absorption. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure. - Warfarin: monitor INR as nilotinib can affect anticoagulation. - Statins (e.g., simvastatin): increased risk of myopathy; consider dose adjustment.